SARMREV-ERB agonistMetabolic agentNon-steroidalOral

Stenabolic (SR-9009, REV-ERB agonist)

Also known as SR-9009 · SR9009

Written by enwyReviewed 15 Jul 20262 sources0 comments

Stenabolic (SR-9009) is not a SARM but a REV-ERB agonist studied in mice for effects on circadian metabolism, endurance and fat loss. It has essentially no human data and, critically, very poor oral bioavailability, casting doubt on whether oral use produces meaningful effects. It does not act on the androgen receptor, so no steroid profile applies.

01 Overview

SR-9009 activates REV-ERB, a nuclear receptor tied to the circadian clock and metabolic gene expression. In mice it increased mitochondrial content, endurance and fat metabolism, generating strong recreational interest as an exercise-mimetic.

However, published pharmacology indicates SR-9009 has poor oral bioavailability, so orally dosed effects in humans are questionable and unproven. There are no human trials of efficacy or safety. It is banned in sport and sold only as a research chemical, with all dosing based on anecdote.

02 Mechanism

Agonist of the REV-ERB nuclear receptors, modulating circadian and metabolic gene programs to increase fatty-acid oxidation and mitochondrial activity in animal models.

03 Dosing

Tier	Dose	Route	Notes
Common	20–30 mg/day	Oral	Anecdotal; often split into several doses because of the short half-life and poor oral absorption.

04 Effects

Effect	Magnitude	Evidence
Increased enduranceMice showed improved running endurance and mitochondrial function; not shown in humans and undermined by poor oral bioavailability.		Preclinical
Enhanced fat metabolismAnimal data show increased fat oxidation and weight loss.		Preclinical
Subjective energy and fat lossSome users report effects, though these are hard to reconcile with the poor oral absorption.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Unknown human safety profileNo human trials exist; short- and long-term safety are uncharacterised.	Moderate	Unknown	Unconfirmed
Circadian and sleep disruptionBecause it targets the circadian clock, effects on sleep and rhythm are plausible; unconfirmed in humans.	Mild	Unknown	Preclinical

06 Legal status

United States

Not FDA-approved; unlawful as dietary supplement

as of

Prohibited at all times by WADA

as of

07 References

REV-ERB agonist SR9009 and metabolic effects in micePubMed

SR9009 pharmacokinetics and oral bioavailabilityPubMed

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.